Shota Tsukimoto

Dr. Shota Tsukimoto

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 December 2023 in Medicina
Verified
Journal Article
Open access
PDF file
AKAtsuhiro Kitaura
Atsuhiro Kitaura
HSHiroatsu Sakamoto Sakamoto
Hiroatsu Sakamoto Sakamoto
SHShinichi Hamasaki
Shinichi Hamasaki
STShota Tsukimoto
Shota Tsukimoto
YNYasufumi Nakajima
Yasufumi Nakajima
Background and Objectives: Remimazolam is a new ultrashort-acting benzodiazepine anesthetic. Remimazolam appears to be useful in patients with severe valvular disease because of its minimal cardiovascular impact. In this retrospective case series study, we assessed the efficacy and safety of remimazolam for maintaining hemodynamic stability during anesthetic induction and maintenance. Cases: MitraClip was performed on 18 cases with severe mitral regurgitation with low left ventricular function who presented with heart failure, and remimazolam was administered for general anesthesia with induction (12 mg/kg/h) and maintenance (1 mg/kg/h). The impact of remimazolam on the hemodynamics at anesthetic induction and during anesthetic maintenance was investigated retrospectively using electronic medical records. Blood pressure decreased significantly during anesthetic induction with remimazolam (78.5 [72, 81.25] and 66.1 [62.2, 74.2], median [IQR], p = 0.0001), but only mildly, by about 10 mmHg. There was no significant change in the cardiac index (2.0 [1.8, 2.4] vs. 1.9 [1.8, 2.3], p = 0.57642) or pulse rate (73.5 ± 8.85 vs. 74.7 ± 11.7, mean ± SD, p = 0.0876) during anesthetic induction with remimazolam. All patients underwent MitraClip without major hemodynamic concerns, with no or small increases in inotropes. Conclusions: Remimazolam may be used safely in patients with severe mitral regurgitation and low left ventricular function presenting with heart failure.

14 March 2024 in Immunity, Inflammation and Disease
Verified
Journal Article
Open access
STShota Tsukimoto
Shota Tsukimoto
AKAtsuhiro Kitaura
Atsuhiro Kitaura
HKHidetaka Kuroda
Hidetaka Kuroda
UIUno Imaizumi
Uno Imaizumi
FYFumihiko Yoshino
Fumihiko Yoshino
TSTakuro Sanuki
Takuro Sanuki
Background: Anesthetic agents, particularly intravenous anesthetics, may affect immune function and tumorigenic factors. We herein investigated whether the anti‐inflammatory effects of anesthetic agents are attributed to their antioxidant properties. The antioxidant and anti‐inflammatory effects of remimazolam, a new anesthetic, remain unclear. We hypothesized that remimazolam exerts anti‐inflammatory effects due to its antioxidant properties, which may affect the postoperative inflammatory response. This retrospective clinical study examined this hypothesis using laboratory and clinical approaches.Methods: The antioxidant effects of remimazolam and dexmedetomidine were assessed by electron spin resonance (ESR) spectroscopy, and postoperative inflammatory responses were compared in 143 patients who underwent transcatheter aortic valve replacement at Kindai University Hospital between April 2021 and December 2022. The primary endpoint was the presence or absence of the antioxidant effects of the anesthetics themselves using ESR.Results: Remimazolam at clinical concentrations exerted antioxidant effects, whereas dexmedetomidine did not. Increases in C‐reactive protein (CRP) levels on POD3 from preoperative values were significantly smaller in the remimazolam group than in the dexmedetomidine group (1.33 ± 1.29 vs. 2.17 ± 1.84, p = .014).Conclusions: Remimazolam exerted stronger anti‐inflammatory effects than dexmedetomidine, and these effects were enhanced by its antioxidant properties, which may have affected postoperative CRP production.

15 April 2024 in Cureus
Verified
Journal Article
Open access
STShota Tsukimoto
Shota Tsukimoto
AKAtsuhiro Kitaura
Atsuhiro Kitaura
RYRina Yamamoto
Rina Yamamoto
CHChikara Hirase
Chikara Hirase
SNShinichi Nakao
Shinichi Nakao
TSTakuro Sanuki
Takuro Sanuki
Purpose: Hypotension is common during anesthesia induction. However, minimal hemodynamic effects of remimazolam anesthesia have been reported. We hypothesized that remimazolam would have weaker hemodynamic effects than would propofol. To test this, we simultaneously evaluated the hemodynamics using the estimated continuous cardiac output (esCCO) system and heart rate variability (HRV) during anesthesia induction. Methods: This was a single-center, observational, retrospective study of patients undergoing dental surgery under general anesthesia between 2020 and 2022. Seventy patients were divided into two groups: remimazolam (R group; n=34) and propofol (P group; n=36). The information obtained from the anesthesia records, patient information, esCCO system parameters, and HRV were integrated and analyzed. The percentages of various parameters were set to 100% for the pre-induction phase as the baseline. Results: The %MAP (noninvasive mean arterial blood pressure) decreased over a narrower range in the R compared to the P group (-17.8% (-26.3%, -11.9%) vs. -22.6% (-32.9%, -17.0%); P=0.039). The %HR (heart rate) increased significantly in the R group and decreased in the P group (+10.7% (+6.5%, +18.6%) vs. -6.5% (-14.5%, +8.4%); P<0.01). The %SV esCCO (stroke volume calculated using the esCCO system) decreased significantly in both groups, but the R group showed a smaller difference compared to the P group (5.1% (7.7%, -2.1%) vs. -10.0% (-13.8%, -5.6%); P<0.01). The rates of change in %LF nu (normalized unit of low frequency) and %HF nu (normalized unit of high frequency) were lower for the R than for the P group, although the difference was not significant (+6.8% (-14.5%, 32.4%) vs. +9.2% (-7.2%, +59.7%), P=0.30; +7.9% (-51.0%, +66.9%) vs. +22.8% (-26.1%, +61.6%), P=0.57). Conclusion: Remimazolam demonstrated a lower MAP reduction rate than propofol. A compensatory increase in HR occurred with a decrease in stroke volume. However, the HR increase was not attributable to the autonomic nervous system.

2 September 2022 in Journal of Dental Sciences
Verified
Journal Article
Open access
KKKeita Kagawa
Keita Kagawa
HKHidetaka Kuroda
Hidetaka Kuroda
DKDai Kaneko
Dai Kaneko
MIMiki Imura
Miki Imura
UIUno Imaizumi
Uno Imaizumi
TSTakuro Sanuki
Takuro Sanuki
Although many coronavirus disease 2019 (COVID-19) vaccine injections have been administered worldwide, the safety of this practice remains unclear. This study aimed to compare the rates of complications associated with COVID-19 vaccines administered by dentists with those of vaccines administered by nurses. This study aimed to evaluate the safety of a vaccination program delivered by dentists. This observational cohort study included 537 recipients of the second dose of the Pfizer COVID-19 vaccine, delivered as an intramuscular injection to the upper arm deltoid muscle by dentists or nurses at the study site. Vaccine recipients were divided into two groups according to the vaccination administrator (dentist vs. nurse groups). The rates of complications associated with intramuscular injection technique (numbness in the hand or arm at the time of the injection, vasovagal reflex at the time of the injection, vaccine-related shoulder injury, and prolonged numbness) were examined. A total of 125 vaccine recipients were included (nurse group, n = 84; dentist group, n = 41). The overall incidence rate of complications was lower in the dentist group (2.4%; 1/41) than in the nurse group (8.3%; 7/84). However, this difference was not statistically significant (P = 0.3). This study suggests that the safety of COVID-19 vaccine administration is comparable between dentists and nurses.

Verified
Journal Article
Open access
PDF file
TMTakashi Mino
Takashi Mino
AKAtsuhiro Kitaura
Atsuhiro Kitaura
HSHiroatsu Sakamoto Sakamoto
Hiroatsu Sakamoto Sakamoto
YYYukari Yoshino
Yukari Yoshino
STShota Tsukimoto
Shota Tsukimoto
YNYasufumi Nakajima
Yasufumi Nakajima
Background/Objectives: Remimazolam, a short-acting benzodiazepine, promotes quick and consistent recovery from anesthesia. However, flumazenil’s rapid antagonistic effects on benzodiazepines during the emergence from anesthesia are thought to increase the risk of postoperative nausea and vomiting (PONV). This study aimed to compare the rate of PONV in monitored anesthesia care (MAC) with remimazolam versus conventional MAC with dexmedetomidine. Methods: This single-center retrospective study included all cases with transcatheter aortic valve replacements (TAVR) performed using MAC at our institution between January 2019 and April 2023. The patients were divided into remimazolam and dexmedetomidine–propofol groups based on the anesthetic method used. We used propensity score matching at a 1:1 ratio to account for the patient backgrounds. The primary outcome measure was the rate of PONV within 48 h. Secondary outcome measures included the severity of PONV and the number of antiemetics administered. Results: This study included 177 subjects. Following propensity score matching, 61 patients were allocated to each group. The incidence of PONV within 48 h after surgery was 4.92% in the remimazolam group and 3.28% in the dexmedetomidine–propofol group, with no significant difference between the two groups (p = 0.817). There was no significant difference between the two groups in terms of the secondary outcomes, including the severity of PONV (p = 0.190) and the use of antiemetics (p = 0.690). Conclusions: In TAVR with MAC and remimazolam, the incidence of PONV within 48 h was comparable to that of dexmedetomidine.

17 April 2022 in Viruses
Verified
Journal Article
Open access
PDF file
STShota Tsukimoto
Shota Tsukimoto
YHYoshiyuki Hakata
Yoshiyuki Hakata
STSachiyo Tsuji-Kawahara
Sachiyo Tsuji-Kawahara
TETakuji Enya
Takuji Enya
TTTetsuo Tsukamoto
Tetsuo Tsukamoto
MMMasaaki Miyazawa
Masaaki Miyazawa
Tissue and subcellular localization and its changes upon cell activation of virus-restricting APOBEC3 at protein levels are important to understanding physiological functions of this cytidine deaminase, but have not been thoroughly analyzed in vivo. To precisely follow the possible activation-induced changes in expression levels of APOBEC3 protein in different mouse tissues and cell populations, genome editing was utilized to establish knock-in mice that express APOBEC3 protein with an in-frame FLAG tag. Flow cytometry and immunohistochemical analyses were performed prior to and after an immunological stimulation. Cultured B cells expressed higher levels of APOBEC3 protein than T cells. All differentiation and activation stages of freshly prepared B cells expressed significant levels of APOBEC3 protein, but germinal center cells possessed the highest levels of APOBEC3 protein localized in their cytoplasm. Upon immunological stimulation with sheep red blood cells in vivo, germinal center cells with high levels of APOBEC3 protein expression increased in their number, but FLAG-specific fluorescence intensity in each cell did not change. T cells, even those in germinal centers, did not express significant levels of APOBEC3 protein. Thus, mouse APOBEC3 protein is expressed at distinctively high levels in germinal center B cells. Antigenic stimulation did not affect expression levels of cellular APOBEC3 protein despite increased numbers of germinal center cells.